Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Tiziana Life Sciences LtdNASDAQ: TLSA
Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025
Capital expenditures grows 275.5% year over year
Q4 FY2025 capital expenditures of $15K (cash outflow) rose 275.5% year over year.
Context
- Capital expenditures increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (21K) USD
- Year-over-year change
- -38.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21K) | -38.3% |
| FY2024 | 2024-12-31 | (15.18K) | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (16.31K) | — |
Capital Expenditures vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 capital expenditures of $21K is the 7th largest of the 9 companies compared; the peer median is $154.24K.
- Its year-over-year change of +38.3% is the 2nd highest of 8, against a peer median of -37.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.73M | -37.7% | -19.2% | 1.1% | |
| LTM Mar 2026 | $697.7K | -26.1% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $552K | -66.6% | +7.5% | 7.7% |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $196.47K | -29.5% | -3.0% | — |
| LTM Mar 2026 | $112K | -95.7% | -40.3% | — | |
| LTM Mar 2026 | $34K | -81.2% | — | — | |
| FY2025 | $21K | +38.3% | — | — | |
| FY2025 | $1.21K | +40166.7% | -10.2% | — | |
| LTM Mar 2026 | $3 | — | — | 0.0% | |
| Peer median (excluding TLSA) | $154.24K | -37.7% | -10.2% | 1.1% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.36M) | (12.55M) | (14M) | (9.48M) | (18.43M) |
| Depreciation & Amortization | 104.52K | 41.57K | 75.97K | 99.09K | 234K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (573.01K) | (948.89K) | (1.25M) | (441.1K) | 3.06M |
| Accounts Receivables | 317.27K | (127.17K) | (1.14M) | (1.11M) | (692K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (890.27K) | (821.72K) | (109.21K) | 670.44K | 3.75M |
| Other Non-Cash Items | 1.7M | (2.53M) | 2.75M | 8.6M | 2.29M |
| Operating Cash Flow | (16.13M) | (15.99M) | (12.42M) | (1.22M) | (12.85M) |
| Capital Expenditures | (16.31K) | 0 | 0 | (15.18K) | (21K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (2.18M) | (791.35K) | (52K) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112.67K | (1.08M) | (200.21K) | 10.45K | 3.06M |
| Investing Cash Flow | 96.37K | (3.26M) | (991.57K) | (56.74K) | 3.04M |
| Debt Repayment | 0 | 0 | 0 | (141K) | 0 |
| Common Stock Issued | 95.62K | 0 | 125.83K | 3.71M | 10.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.67K) | (44.84K) | (94.17K) | 28.33K | (196K) |
| Financing Cash Flow | (17.05K) | (44.84K) | 31.65K | 3.6M | 10.01M |
| Effect of Forex Changes | (1.53M) | (324.45K) | (22.16K) | (293.27K) | 84K |
| Net Change in Cash | (17.59M) | (19.62M) | (13.4M) | 2.03M | 286K |
| Free Cash Flow | (16.15M) | (15.99M) | (12.42M) | (1.23M) | (12.87M) |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.